NCT06161220View on ClinicalTrials.gov

A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

December 3, 2023

Study Completion Date

December 5, 2023

Conditions
Cardiac Repolarization in Healthy Subjects
Interventions
DRUG

Carbidopa capsule

Dose: 4x 100 mg

DRUG

Moxifloxacin Tablets, USP

Dose: 400 mg

DRUG

Placebo

Placebo capsules matching the carbidopa capsules

Trial Locations (1)

56529-1342

AXIS Clinicals, LLC, Dilworth

Sponsors
All Listed Sponsors
lead

Impax Laboratories, LLC

INDUSTRY

NCT06161220 - A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects | Biotech Hunter | Biotech Hunter